Immunomodulator therapy migration in relapsing remitting multiple sclerosis: a study of 152 cases

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Immunomodulatory drugs have been utilized for Relapsing Remitting Multiple Sclerosis (RRMS) treatment since 1997.
• These treatments have significantly altered the natural history of RRMS.

Purpose of the Study:

• To document the experience of the Multiple Sclerosis Attendance and Treatment Center (CATEM) in treating RRMS patients with immunomodulators.
• To analyze adherence, migration, withdrawal, and progression rates in RRMS patients undergoing immunomodulatory therapy.

Main Methods:

• RRMS patients receiving continuous immunomodulator therapy were assessed.
• Patients were stratified into three groups based on the duration of immunomodulator intake.
• Key outcome measures included adherence, drug withdrawal, patient migration, and disease progression.

Main Results:

• Adherence rates varied across groups, with Group 1 showing 74% adherence and Group 2 showing 88%.
• Progression to Secondary Progressive Multiple Sclerosis (SPMS) occurred in 31% of Group 2 patients and 26% of Group 3 patients.
• Therapeutic failure was the primary driver for migration, affecting approximately one-third of patients, with a mean migration time of 0.5-2.5 years in Group 3.

Conclusions:

• Immunomodulatory treatment for RRMS is associated with notable failure rates and potential side effects.
• Observed adherence levels align with findings reported in international literature.
• Continuous monitoring and evaluation are crucial for managing RRMS treatment efficacy.